Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CYP3A4

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: CYP3A4. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2014-004554-34 Sponsor Protocol Number: 2014-004554-34 Start Date*: 2015-10-15
    Sponsor Name:Bispebjerg Hospital
    Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004032-29 Sponsor Protocol Number: M18CYP Start Date*: 2019-01-23
    Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
    Full Title: Effect of the moderate CYP3A4-inhibitor erythromycin on the pharmacokinetics of palbociclib
    Medical condition: Patients for whom palbociclib is standard of care (breast cancer)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000796-17 Sponsor Protocol Number: AKF-373 Start Date*: 2008-03-10
    Sponsor Name:Institut for Sundhedstjenesteforskning, Klinisk Farmakologi, Syddansk Universitet
    Full Title: Optagelse af svampemidlet miconazol og effekt på østrogenmetaboliserende enzymer i mennesker
    Medical condition:
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003954-26 Sponsor Protocol Number: STAR22 Start Date*: 2019-01-30
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy
    Medical condition: Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004854-12 Sponsor Protocol Number: N19RER Start Date*: 2019-04-12
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib
    Medical condition: Advanced EGFR mutation positive non small cell lung cancer, pancreatic carcinoma, colorectal cancer and biliary cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003347-73 Sponsor Protocol Number: UMCN-AKF 07.02 Start Date*: 2007-12-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE).
    Medical condition: Nausea and vomiting after using moderate emetogenic cytostatics such as etoposide and cisplatin for the treatment of patients with metastatic lung carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004158-33 Sponsor Protocol Number: CYP3A4/5+PGPinRenalTx Start Date*: 2008-09-17
    Sponsor Name:Department of Nephrology and Renal Transplantation, KU Leuven
    Full Title: CYP3A4/5 and PGP activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and...
    Medical condition: Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant med...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004069-16 Sponsor Protocol Number: CYP3A4/5RenalTx Start Date*: 2007-10-19
    Sponsor Name:Department of Nephrology and Renal Transplantation, KU Leuven
    Full Title: Hepatic and intestinal CYP3A4/5 activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings af...
    Medical condition: Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant me...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004267-22 Sponsor Protocol Number: 2348/2007 Start Date*: 2007-11-15
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pharmacogenetic evaluation of oxicodone in patients.
    Medical condition: Cancer chronic pain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004044-28 Sponsor Protocol Number: AKF-396 Start Date*: 2020-12-18
    Sponsor Name:University of Southern Denmark
    Full Title: Flucloxacillin as an inducer of CYP-enzymes
    Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001655-41 Sponsor Protocol Number: 35RC19_8877_DIPLOID Start Date*: 2020-09-15
    Sponsor Name:CHU de Rennes
    Full Title: P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-release
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004104-34 Sponsor Protocol Number: SNDX-5613-0700 Start Date*: 2022-04-20
    Sponsor Name:Syndax Pharmaceuticals, Inc
    Full Title: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nu...
    Medical condition: Relapsed or Refractory Acute Leukemias
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024330 Leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) DE (Temporarily Halted) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005998-27 Sponsor Protocol Number: AKF-398 Start Date*: 2021-03-12
    Sponsor Name:University of Southern Denmark
    Full Title: Interleukin-6 inhibitors and drug-drug interactions in patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10060732 Rheumatoid arthritis flare up LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001976-19 Sponsor Protocol Number: AKF-371 Start Date*: 2006-06-12
    Sponsor Name:Institut for Sundhedstjenesteforskning, Klinisk Farmakologi, Syddansk Universitet
    Full Title: “Betydningen af CYP2C19 polymorfi for escitaloprams farmakokinetik og farmakodynamik, målt som ændringer i pupildiameter”
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005843-24 Sponsor Protocol Number: RIFA+UDCA Start Date*: 2006-02-23
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Studie på effekten av rifampicin och ursodeoxycholsyra på gallipider och deras transport och avgiftning hos patienter med kolesterolgallstenar.
    Medical condition: Gallstone disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023776-52 Sponsor Protocol Number: Lisette-1 Start Date*: 2011-01-19
    Sponsor Name:
    Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002217-31 Sponsor Protocol Number: 2215-CL-0101 Start Date*: 2015-07-09
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Medical condition: Relapsed or Refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-05-04
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-016176-78 Sponsor Protocol Number: 2009-016176-78 Start Date*: 2010-02-08
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Terapy with everolimus in liver transplant.
    Medical condition: liver transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019805 SOC
    9.1 10016152 LLT
    9.1 10016152 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:12:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA